JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hibell, A. D.
Right arrow Articles by Michel, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hibell, A. D.
Right arrow Articles by Michel, A. D.

Vol. 296, Issue 3, 947-957, March 2001

Complexities of Measuring Antagonist Potency at P2X7 Receptor Orthologs

A. D. Hibell, K. M. Thompson, M. Xing, P. P. A. Humphrey and A. D. Michel

Glaxo Institute of Applied Pharmacology, Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom

The ability of P2 antagonists to affect agonist-stimulated fluorescent dye accumulation in cells expressing human, rat, or mouse P2X7 receptors was examined. Several compounds, including pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), which was previously thought to be a weak P2X7 receptor antagonist, possessed high potency (nanomolar IC50) at human and rat P2X7 receptors. However, there were species differences in antagonist potency with PPADS, pyridoxal 5'-phosphate (P5P), and periodate-oxidized ATP (OxATP) exhibiting 20- to 500-fold higher potency for human than for mouse P2X7 receptors. HMA (5-(N,N-hexamethylene)amiloride) was also selective for human over rat P2X7 receptors but potentiated responses at mouse P2X7 receptors. Coomassie Brilliant Blue G (CBB) was a nonselective antagonist with high potency at mouse P2X7 receptors (IC50 ~ 100 nM). All compounds were noncompetitive antagonists, and potency could only be quantified by measuring IC50 values. These values were similar when determined against EC50 concentrations of ATP or 2'- and 3'-O-4(-benzoylbenzoyl)-ATP and, for most compounds, only slightly (3- to 5-fold) affected by agonist concentration. However, IC50 values for KN62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine) and suramin, varied up to 25-fold depending upon agonist concentration. Furthermore, IC50 values for KN62 and OxATP were 10-fold lower at 22°C than at 37°C, whereas IC50 values for PPADS, P5P, suramin, and OxATP were up to 20-fold lower in NaCl than in sucrose buffer. Potency estimates for CBB and PPADS decreased 5-fold in the presence of bovine serum albumin, possibly due to protein binding. Given the species differences, and the effects of assay conditions on antagonist potency, caution must be exercised when interpreting results obtained with the available antagonists.

0022-3565/01/2963-0947$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
T. Noguchi, K. Ishii, H. Fukutomi, I. Naguro, A. Matsuzawa, K. Takeda, and H. Ichijo
Requirement of Reactive Oxygen Species-dependent Activation of ASK1-p38 MAPK Pathway for Extracellular ATP-induced Apoptosis in Macrophage
J. Biol. Chem., March 21, 2008; 283(12): 7657 - 7665.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
D. Tong, T. Y. Li, K. E. Naus, D. Bai, and G. M. Kidder
In vivo analysis of undocked connexin43 gap junction hemichannels in ovarian granulosa cells
J. Cell Sci., November 15, 2007; 120(22): 4016 - 4024.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. Sluyter, A. N. Shemon, W. E. Hughes, R. O. Stevenson, J. G. Georgiou, G. D. Eslick, R. M. Taylor, and J. S. Wiley
Canine erythrocytes express the P2X7 receptor: greatly increased function compared with human erythrocytes
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R2090 - R2098.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
W. Ma, A. Korngreen, S. Weil, E. B.-T. Cohen, A. Priel, L. Kuzin, and S. D. Silberberg
Pore properties and pharmacological features of the P2X receptor channel in airway ciliated cells
J. Physiol., March 15, 2006; 571(3): 503 - 517.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Kawamura, F. Aswad, M. Minagawa, S. Govindarajan, and G. Dennert
P2X7 Receptors Regulate NKT Cells in Autoimmune Hepatitis
J. Immunol., February 15, 2006; 176(4): 2152 - 2160.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
R. X. Faria, F. P. DeFarias, and L. A. Alves
Are second messengers crucial for opening the pore associated with P2X7 receptor?
Am J Physiol Cell Physiol, February 1, 2005; 288(2): C260 - C271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
J. F. Hiken and T. H. Steinberg
ATP downregulates P2X7 and inhibits osteoclast formation in RAW cells
Am J Physiol Cell Physiol, August 1, 2004; 287(2): C403 - C412.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Adriouch, C. Dox, V. Welge, M. Seman, F. Koch-Nolte, and F. Haag
Cutting Edge: A Natural P451L Mutation in the Cytoplasmic Domain Impairs the Function of the Mouse P2X7 Receptor
J. Immunol., October 15, 2002; 169(8): 4108 - 4112.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
R. A. North
Molecular Physiology of P2X Receptors
Physiol Rev, October 1, 2002; 82(4): 1013 - 1067.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.